NeurologyLive - Clinical Neurology News and Neurology Expert Insights articleshttps://www.neurologylive.com/newsNeurologyLive - Clinical Neurology News and Neurology Expert Insights articles© 2026 MJH Life Sciences™ and NeurologyLive - Clinical Neurology News and Neurology Expert Insights. All rights reserved.Mon, 29 Jun 2026 19:36:31 +00005en-us14447https://www.neurologylive.com/newshttps://www.neurologylive.com/logo.webphttps://www.neurologylive.com/view/evaluating-oral-btk-inhibitor-remibrutinib-phase-3-study-generalized-mg-relieve-trialhttps://www.neurologylive.com/view/evaluating-oral-btk-inhibitor-remibrutinib-phase-3-study-generalized-mg-relieve-trial<![CDATA[The ongoing phase 3 RELIEVE trial investigates the efficacy and safety of remibrutinib in patients with generalized myasthenia gravis who are on stable standard-of-care treatment.]]>Mon, 29 Jun 2026 19:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/multidimensional-cognitive-training-improves-cognition-mood-quality-of-life-postoperative-glioma-patients-trial-findshttps://www.neurologylive.com/view/multidimensional-cognitive-training-improves-cognition-mood-quality-of-life-postoperative-glioma-patients-trial-finds<![CDATA[A non-randomized controlled trial found that an MCT program added to standard rehabilitation significantly improved MoCA scores and reduced anxiety and depression at 4 and 12 weeks compared with standard care alone.]]>Mon, 29 Jun 2026 17:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/former-nfl-running-back-chris-johnson-diagnosed-als-at-40https://www.neurologylive.com/view/former-nfl-running-back-chris-johnson-diagnosed-als-at-40<![CDATA[Johnson, who set the single-season NFL rushing record in 2009, went public with his diagnosis on Good Morning America, saying he hopes his story accelerates research and awareness of the disease.]]>Mon, 29 Jun 2026 14:30:21 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/managing-infection-risk-and-safety-monitoring-with-anti-cd20-ms-disease-modifying-therapyhttps://www.neurologylive.com/view/managing-infection-risk-and-safety-monitoring-with-anti-cd20-ms-disease-modifying-therapy<![CDATA[In this episode titled "Managing Infection Risk and Safety Monitoring with Anti-CD20 MS Disease Modifying Therapy," Dr. Williams raises the issue of infection risk — a topic of increasing clinical relevance.]]>Mon, 29 Jun 2026 12:05:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/long-term-efficacy-of-anti-cd20-therapies-in-ms-what-the-evidence-showshttps://www.neurologylive.com/view/long-term-efficacy-of-anti-cd20-therapies-in-ms-what-the-evidence-shows<![CDATA[With the first anti-CD20 therapy approved for MS now more than ten years in clinical use, in this episode titled "Long-Term Efficacy of Anti-CD20 Therapies in MS: What the Evidence Shows," Dr. Williams asks Dr. Krieger what the long-term evidence reveals about efficacy — and whether there have been any surprises.]]>Mon, 29 Jun 2026 12:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/phase-2-trial-lrrk2-inhibitor-neu-411-expands-following-michael-j-fox-foundation-granthttps://www.neurologylive.com/view/phase-2-trial-lrrk2-inhibitor-neu-411-expands-following-michael-j-fox-foundation-grant<![CDATA[A $2.5 million Michael J. Fox Foundation grant is funding 4 new sites for the NEULARK trial assessing NEU-411 as a potential disease-modifying therapy in genetically selected patients with early Parkinson disease.]]>Mon, 29 Jun 2026 12:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/this-week-on-neurologylive-june-29-2026https://www.neurologylive.com/view/this-week-on-neurologylive-june-29-2026<![CDATA[Here's some of what is coming soon to NeurologyLive® this week. ]]>Mon, 29 Jun 2026 10:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/neurologylive-brain-games-june-28-2026https://www.neurologylive.com/view/neurologylive-brain-games-june-28-2026<![CDATA[Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sex-based differences in neurology!]]>Sun, 28 Jun 2026 10:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/improving-recognition-autonomic-dysfunction-parkinson-disease-insights-jonathan-isaacson-abhishek-lenkahttps://www.neurologylive.com/view/improving-recognition-autonomic-dysfunction-parkinson-disease-insights-jonathan-isaacson-abhishek-lenka<![CDATA[Movement disorder experts Jonathan Isaacson, MD, and Abhishek Lenka, MD, PhD, discuss early identification and accurate diagnosis of autonomic dysfunction in Parkinson disease, highlighting emerging biomarkers and monitoring tools that may enable more personalized care.]]>Sat, 27 Jun 2026 19:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/preoperative-putamen-volume-predicts-gpi-dbs-response-hie-related-dystonia-dyskinesia-study-findshttps://www.neurologylive.com/view/preoperative-putamen-volume-predicts-gpi-dbs-response-hie-related-dystonia-dyskinesia-study-finds<![CDATA[A recently published 20-year study suggests that preoperative putamen volume on MRI independently can predict motor response to GPi-DBS in patients with dystonia-dyskinesia syndrome secondary to perinatal hypoxic-ischemic encephalopathy. ]]>Sat, 27 Jun 2026 15:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/neurologylive-friday-5-june-26-2026https://www.neurologylive.com/view/neurologylive-friday-5-june-26-2026<![CDATA[Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 26, 2026. ]]>Fri, 26 Jun 2026 19:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/clinical-impact-fda-expanded-efgartigimod-label-josh-alpershttps://www.neurologylive.com/view/clinical-impact-fda-expanded-efgartigimod-label-josh-alpers<![CDATA[Following the FDA's expanded approval of efgartigimod, the neuromuscular physician at Erlanger Health Systems discusses the implications for seronegative disease, treatment sequencing, and the evolving definition of antibody-negative MG. [WATCH TIME: 5 minutes]]]>Fri, 26 Jun 2026 17:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/step-by-step-ucsf-real-time-adaptive-dbs-approach-parkinson-diseasehttps://www.neurologylive.com/view/step-by-step-ucsf-real-time-adaptive-dbs-approach-parkinson-disease<![CDATA[Doris D. Wang, MD, PhD, Associate Professor of Neurological Surgery at UCSF, discusses a newly published adaptive deep brain stimulation system that adjusts in real time during walking and what it means for the future of Parkinson disease care.]]>Fri, 26 Jun 2026 15:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/episode-169-clinical-guide-to-diagnosing-and-managing-ademhttps://www.neurologylive.com/view/episode-169-clinical-guide-to-diagnosing-and-managing-adem<![CDATA[Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Grace Gombolay, MD; and Varun Kannan, MD. [LISTEN TIME: 25 minutes]]]>Fri, 26 Jun 2026 10:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/recognizing-addressing-demoralization-parkinson-diseasehttps://www.neurologylive.com/view/recognizing-addressing-demoralization-parkinson-disease<![CDATA[At ATMRD 2026, a neurologist at UCLA discussed the growing recognition of demoralization in Parkinson disease, highlighting how it differs from depression and apathy and outlining strategies to help patients maintain resilience, purpose, and quality of life. [Watch time: 5 minutes] ]]>Thu, 25 Jun 2026 22:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/fda-clears-path-navsunli-bla-resubmission-mps-ii-no-additional-studies-requiredhttps://www.neurologylive.com/view/fda-clears-path-navsunli-bla-resubmission-mps-ii-no-additional-studies-required<![CDATA[REGENXBIO expects to resubmit the BLA for clemidsogene lanparvovec in Q3 2026 after the FDA confirmed existing CAMPSIITE data are sufficient for accelerated approval consideration.]]>Thu, 25 Jun 2026 16:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/tolebrutinib-approved-eu-nonrelapsing-secondary-progressive-ms-marking-first-disability-targeting-therapy-indicationhttps://www.neurologylive.com/view/tolebrutinib-approved-eu-nonrelapsing-secondary-progressive-ms-marking-first-disability-targeting-therapy-indication<![CDATA[The European Commission has approved Cenrifki (tolebrutinib) for nrSPMS without relapses in the last two years, a milestone that arrives despite the drug's failed US submission and a regulatory pathway that has been anything but linear.]]>Thu, 25 Jun 2026 14:06:23 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/choosing-appropriate-candidates-for-ofatumumab-treatment-in-relapsing-mshttps://www.neurologylive.com/view/choosing-appropriate-candidates-for-ofatumumab-treatment-in-relapsing-ms<![CDATA[Williams outlines how active disease features, lifestyle needs, and prior experience with injectable therapies inform selection of ofatumumab as a high-efficacy, self-administered option for patients with relapsing multiple sclerosis.]]>Thu, 25 Jun 2026 12:05:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/positioning-ofatumumab-among-high-efficacy-therapies-in-relapsing-mshttps://www.neurologylive.com/view/positioning-ofatumumab-among-high-efficacy-therapies-in-relapsing-ms<![CDATA[Williams describes how the shift toward early use of high-efficacy therapy in relapsing MS has brought ofatumumab, an at-home, subcutaneous anti-CD20 agent, into treatment discussions at the start of the disease course.]]>Thu, 25 Jun 2026 12:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/streamlining-genetic-screening-recruitment-lrrk2-targeted-pd-trial-james-beckhttps://www.neurologylive.com/view/streamlining-genetic-screening-recruitment-lrrk2-targeted-pd-trial-james-beck<![CDATA[The chief scientific officer of the Parkinson’s Foundation discussed how the PD Trial Navigator program helps to identify individuals with Parkinson Disease who may be eligible for the phase 2 NEULARK study. [WATCH TIME: 4 minutes]]]>Thu, 25 Jun 2026 10:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/new-deep-learning-tool-forecasts-alzheimer-disease-progression-baseline-mrihttps://www.neurologylive.com/view/new-deep-learning-tool-forecasts-alzheimer-disease-progression-baseline-mri<![CDATA[Ashish Raj, PhD, professor of radiology and biomedical imaging at UCSF, discusses a newly developed AI model that predicts current and future cognitive impairment from a single baseline MRI scan in patients across the Alzheimer disease spectrum.]]>Wed, 24 Jun 2026 19:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/using-serum-biomarkers-monitor-ms-disease-activity-darin-okudahttps://www.neurologylive.com/view/using-serum-biomarkers-monitor-ms-disease-activity-darin-okuda<![CDATA[The professor of neurology at UT Southwestern Medical Center discussed the Octave Multiple Sclerosis Disease Activity Test as a complementary tool to MRI and clinical assessment in MS. [WATCH TIME: 6 minutes]]]>Wed, 24 Jun 2026 17:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/pride-month-2026-understanding-seizure-risk-gender-affirming-hormone-therapyhttps://www.neurologylive.com/view/pride-month-2026-understanding-seizure-risk-gender-affirming-hormone-therapy<![CDATA[A duo of neurologists discussed a new analysis suggesting that gender-affirming hormone therapy was not associated with an increased risk of seizure-related hospitalization among transgender women.]]>Wed, 24 Jun 2026 15:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/indigo-trial-context-vorasidenib-and-early-treatment-in-idh-mutant-gliomahttps://www.neurologylive.com/view/indigo-trial-context-vorasidenib-and-early-treatment-in-idh-mutant-glioma<![CDATA[The discussion turns to the pivotal INDIGO trial, with a focus on how vorasidenib improved progression-free survival and introduced a new early treatment strategy for patients with grade 2 IDH-mutant glioma following surgery ]]>Wed, 24 Jun 2026 12:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/neurovoices-michael-coleman-understanding-programmed-axon-death-therapeutic-potentialhttps://www.neurologylive.com/view/neurovoices-michael-coleman-understanding-programmed-axon-death-therapeutic-potential<![CDATA[The professor of neuroscience at the University of Cambridge discussed the biology of programmed axon death, the emergence of SARM1-targeted therapies, and the challenges of translating this pathway into treatments for neurologic conditions.]]>Wed, 24 Jun 2026 10:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/gene-therapy-amt-260-shows-early-seizure-reductions-refractory-mesial-temporal-lobe-epilepsy-phase-1-cohorthttps://www.neurologylive.com/view/gene-therapy-amt-260-shows-early-seizure-reductions-refractory-mesial-temporal-lobe-epilepsy-phase-1-cohort<![CDATA[Three of six patients in the first low-dose cohort achieved seizure reductions of 79% to 100% at months four through six, with no serious adverse events reported to date.]]>Tue, 23 Jun 2026 22:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/pipeline-review-alzheimer-disease-therapies-mechanism-actionhttps://www.neurologylive.com/view/pipeline-review-alzheimer-disease-therapies-mechanism-action<![CDATA[The 2026 Alzheimer disease drug development landscape highlights a growing shift toward diverse disease-modifying strategies, from amyloid and tau targeting to metabolic and neuroprotective approaches.]]>Tue, 23 Jun 2026 17:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/fda-clears-investigational-new-drug-application-remyelinating-agent-ptd802-multiple-sclerosishttps://www.neurologylive.com/view/fda-clears-investigational-new-drug-application-remyelinating-agent-ptd802-multiple-sclerosis<![CDATA[FDA’s clearance for PTD802, a first-in-class GPR17 antagonist designed to promote remyelination, enables initiation of a first-in-human phase 1 study in healthy volunteers and advances a novel regenerative approach for multiple sclerosis.]]>Tue, 23 Jun 2026 15:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/emerging-biomakers-perpheral-neuropathy-beyond-neurofilament-light-chain-brett-morrisonhttps://www.neurologylive.com/view/emerging-biomakers-perpheral-neuropathy-beyond-neurofilament-light-chain-brett-morrison<![CDATA[The associate professor at Johns Hopkins University discussed emerging biomarkers outside of neurofilament light chain, including muscle MRI, immune-targeted markers, and microRNA research in peripheral nerve disorders. [WATCH TIME: 3 minutes]]]>Tue, 23 Jun 2026 12:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/tardive-dyskinesia-associated-substantially-higher-healthcare-costs-and-resource-use-germany-real-world-claims-analysis-findshttps://www.neurologylive.com/view/tardive-dyskinesia-associated-substantially-higher-healthcare-costs-and-resource-use-germany-real-world-claims-analysis-finds<![CDATA[Patients with incident TD incurred annual all-cause healthcare costs nearly double those of matched non-TD controls, driven primarily by inpatient encounters, while fewer than a quarter received any approved treatment.]]>Tue, 23 Jun 2026 12:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles